TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Recommendation of "Buy" by Brokerages

Key Points

• TScan Therapeutics, Inc. has received an average consensus rating of "Buy" from five research firms, with an average price objective of $7.80.
• Despite a recent 6.9% decline in share price, TScan's quarterly performance exceeded analysts' expectations, reporting $2.17 million in revenue against a consensus of $1.62 million.
• Insider activity is notable, as major shareholder Lynx1 Capital Management LP increased their stake by 25.92% after purchasing over 1.38 million shares at $1.20 each.

TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) has earned an average recommendation of "Buy" from the five brokerages that are covering the firm, Marketbeat reports. Five analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $7.80.

Several brokerages have recently commented on TCRX. Wall Street Zen upgraded shares of TScan Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, July 12th. Wedbush reiterated an "outperform" rating and set a $7.00 target price on shares of TScan Therapeutics in a research report on Tuesday, May 6th. HC Wainwright dropped their target price on shares of TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $9.00 target price on shares of TScan Therapeutics in a research report on Tuesday, April 8th.

TScan Therapeutics Trading Down 2.9%

TCRX traded down $0.05 during mid-day trading on Friday, hitting $1.70. The stock had a trading volume of 55,988 shares, compared to its average volume of 482,226. TScan Therapeutics has a 1-year low of $1.02 and a 1-year high of $6.38. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.55 and a quick ratio of 8.55. The stock's fifty day simple moving average is $1.66 and its 200-day simple moving average is $1.70. The firm has a market capitalization of $96.20 million, a price-to-earnings ratio of -1.56 and a beta of 0.99.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.02. The business had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.62 million. TScan Therapeutics had a negative net margin of 2,974.08% and a negative return on equity of 55.76%. As a group, research analysts forecast that TScan Therapeutics will post -1.12 EPS for the current fiscal year.

Insider Transactions at TScan Therapeutics

In other TScan Therapeutics news, major shareholder Lynx1 Capital Management Lp bought 1,388,794 shares of TScan Therapeutics stock in a transaction dated Monday, May 19th. The stock was acquired at an average cost of $1.20 per share, with a total value of $1,666,552.80. Following the purchase, the insider directly owned 6,746,141 shares in the company, valued at $8,095,369.20. This represents a 25.92% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 4.35% of the company's stock.

Institutional Trading of TScan Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Lynx1 Capital Management LP boosted its holdings in TScan Therapeutics by 2.5% during the 4th quarter. Lynx1 Capital Management LP now owns 5,357,347 shares of the company's stock valued at $16,286,000 after acquiring an additional 132,747 shares during the period. BVF Inc. IL boosted its stake in shares of TScan Therapeutics by 63.6% in the 1st quarter. BVF Inc. IL now owns 4,889,474 shares of the company's stock valued at $6,747,000 after buying an additional 1,900,000 shares during the period. Checkpoint Capital L.P. boosted its stake in shares of TScan Therapeutics by 14.9% in the 1st quarter. Checkpoint Capital L.P. now owns 2,017,650 shares of the company's stock valued at $2,784,000 after buying an additional 261,663 shares during the period. Aberdeen Group plc raised its position in shares of TScan Therapeutics by 0.9% during the 1st quarter. Aberdeen Group plc now owns 891,448 shares of the company's stock worth $1,230,000 after acquiring an additional 7,744 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in TScan Therapeutics by 108.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 280,028 shares of the company's stock worth $851,000 after buying an additional 145,731 shares during the period. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.